Volume, page-19

I am torn on this. I sold AZV back in 2013/14 as it was in my view overvalued and experienced a stellar run from 5c. My view was simply the that the price was baking in more progress than they had actually achieved. But at the same time the CEO made some big promises (as the Eureka Report outlines in the article above) that would of warranted a higher valuation. R&D expenses and transition costs were always going to be elevated and I think Eureka should have taken that into account in their profit numbers, but the question is more in regards to the promised sales growth that looks unlikely at this stage.